Qiagen N.V. (ETR:QIA)
Market Cap | 8.20B |
Revenue (ttm) | 1.91B |
Net Income (ttm) | 80.74M |
Shares Out | n/a |
EPS (ttm) | 0.37 |
PE Ratio | 101.51 |
Forward PE | n/a |
Dividend | 1.21 (3.26%) |
Ex-Dividend Date | Jan 29, 2025 |
Volume | 533,952 |
Average Volume | 676,181 |
Open | 37.87 |
Previous Close | 37.61 |
Day's Range | 37.02 - 37.90 |
52-Week Range | 34.24 - 47.36 |
Beta | 0.62 |
RSI | 55.78 |
Earnings Date | Apr 28, 2025 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial numbers in USD Financial StatementsNews

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These new develop...

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its po...
Activist investor Fivespan takes stake in Qiagen - Bloomberg
Qiagen NV (QGEN) Announces Launch of New Sample Preparation Instruments | QGEN stock news
Qiagen NV (QGEN) Announces Launch of New Sample Preparation Instruments | QGEN stock news

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfol...

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments du...

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time ...

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, M...
Qiagen gains after guidance raise

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen N.V. (NYSE: QGEN) shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the first quarter of 2025 . The company sees net sales growth of a...
Qiagen NV Announces Strong Q1 2025 Results and Updates Full-Year Earnings Outlook
Qiagen NV Announces Strong Q1 2025 Results and Updates Full-Year Earnings Outlook
Qiagen NV (QGEN) Exceeds Q1 2025 Financial Expectations
Qiagen NV (QGEN) Exceeds Q1 2025 Financial Expectations

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting stron...

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earni...

EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook 06-Apr-2025 /...
Qiagen NV Launches Innovative QIAprep& Plasmodium Kit for Malaria Research
Qiagen NV Launches Innovative QIAprep& Plasmodium Kit for Malaria Research

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This...

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria re...

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended De...

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statement...
Qiagen NV (QGEN) Secures FDA Clearance for New Gastrointestinal Panel
Qiagen NV (QGEN) Secures FDA Clearance for New Gastrointestinal Panel

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further...

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared...

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecti...

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringemen...